Erlocip 100mg (Erlotinib)
$22.00
ERLOCIP 100MG (ERLOTINIB) is a targeted cancer treatment medication used primarily for non-small cell lung cancer (NSCLC) and pancreatic cancer. It belongs to a class of drugs called tyrosine kinase inhibitors, which block signals that promote the growth of cancer cells. ERLOCIP 100MG (ERLOTINIB) is taken orally and is most effective when used under strict medical supervision. This precision therapy helps slow disease progression and improve quality of life in eligible patients. Always follow your oncologist’s instructions for best results and regular monitoring.
Quantity
USES OF ERLOCIP TABLET
- Non-small cell lung cancer
- Pancreatic cancer
BENEFITS OF ERLOCIP TABLET
In Non-small cell lung cancer
Non-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Erlocip 100 Tablet helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.
SIDE EFFECTS OF ERLOCIP TABLET
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Erlocip
- Abdominal pain
- Bone pain
- Breathlessness
- Constipation
- Cough
- Diarrhea
- Fatigue
- Fever
- Infection
- Muscle pain
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Vomiting
- Weight loss
HOW TO USE ERLOCIP TABLET
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Erlocip 100 Tablet is to be taken empty stomach.
HOW ERLOCIP TABLET WORKS
Erlocip 100 Tablet is an anti-cancer medication. Epidermal growth factor receptors (EGFR) are expressed on the lung cancer cell surfaces that modulate their growth. This medicine works by binding the chemical messenger, EGFR, hence, inhibits the cancer signaling pathways mediated by EGFR. This is how it restricts further growth of the cancer cells.
